Search clinical trials for: Bevacizumab combined with Sintilimab

Total 1447 results

Tianjin Medical University Cancer Institute and...

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer

Gastric Cancer
Shanghai Chest Hospital

Recruiting

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Non-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesis

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Active, not recruiting

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Hepatocellular Carcinoma Non-resectable

China
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
West China Hospital

Recruiting

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Stomach Neoplasm

China
Zhongda Hospital

Recruiting

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Cholangiocarcinoma

China
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Completed

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Huazhong University of Science and Technology

Recruiting

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Metastatic Colorectal Cancer

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Gastric Cancer

China
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
Xiangya Hospital of Central South University

Not yet recruiting

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

Gastric Cancer
Fudan University

Recruiting

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

Colorectal Liver Metastasis

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Non-small Cell Lung Cancer

China
West China Hospital
Sichuan Provincial People's Hospital; The First People's Hospital of Ziyang; Chengdu... and other collaborators

Not yet recruiting

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Yongchang Zhang

Completed

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Hunan Province Tumor Hospital

Completed

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

Non-small Cell Lung Cancer

China
The First People's Hospital of Changzhou

Not yet recruiting

Regorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC

Colorectal Cancer Metastatic
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Shandong Public Health Clinical Center
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Not yet recruiting

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Advanced Primary Liver Cancer
Sun Yat-sen University

Completed

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
ART Fertility Clinics LLC

Completed

Effectiveness of PGT-A: IVF Versus ICSI

Genetic Condition

United Arab Emirates
University of Lisbon
Associacao Protectora dos Diabeticos de Portugal

Completed

Comparing Moderate and High-intensity Interval Training Protocols on Biomarkers in Type 2 Diabetes Patients (D2FIT)

Type 2 Diabetes
National Taiwan University Hospital

Completed

Synergistic Bilateral Upper-Limb Stroke Rehabilitation Based on Robotic Priming Technique

Stroke Rehabilitation

Taiwan
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
Universite du Quebec en Outaouais

Completed

A Virtual Arm to Stop Smoking

Cigarette Smoking

Canada
University of Rzeszow

Recruiting

Effectiveness of Various Electrotherapy Methods in Treating People With Cervical Spine Pain Syndrome.

Cervical Spine Syndrome

Poland
Changping Laboratory

Not yet recruiting

pBFS-guided cTBS Combined With iTBS Over the Superior Frontal Gyrus for Aphasia After Ischemic Stroke

Aphasia | Stroke, Ischemic
Chap, Linnea I., M.D.
Genentech, Inc.

Unknown

Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study

Breast Cancer

United States
The Second Affiliated Hospital of Shandong First...

Not yet recruiting

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer (RIGHT)

Biliary Carcinoma

China
Medical College of Wisconsin

Completed

A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI

Mild Cognitive Impairment | Memory Disorders | Memory Loss

United States
Hospices Civils de Lyon

Recruiting

ALL Reconstruction Versus Modified Lemaire's LET in Combination With ACL Reconstruction With a Minimum Follow up of 2 Years (ARAVET)

Anterior Cruciate Ligament Injuries

France
Xin-Hua Xu

Unknown

A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xijing Hospital

Recruiting

A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Fujian Medical University Union Hospital

Recruiting

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

Melasma

China
Fudan University

Not yet recruiting

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases (DEBIRI)

Colorectal Neoplasms

China
Lei Liu

Not yet recruiting

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Shandong University

Recruiting

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Objective Response Rate

China

3

Subscribe